Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPM8 | Q7Z2W7 | 4/20 | 0.59 |
| ▸ | PDE2A | O00408 | 6/20 | 0.44 |
| ▸ | P2RX7 | Q99572 | 3/20 | 0.39 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.37 |
| ▸ | RXRA | P19793 | 1/20 | 0.34 |
| ▸ | HNF4A | P41235 | 1/20 | 0.34 |
| ▸ | AURKA | O14965 | 1/20 | 0.34 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.34 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.34 |
| ▸ | ABL1 | P00519 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15567696 | 1.00 | TRPM8 (0.59) | TRPM8PDE2AP2RX7TRPV1RXRA | |
| SCHEMBL15466810 | 0.95 | TRPM8 (0.58) | TRPM8PDE2AP2RX7TRPV1ABL1 | |
| SCHEMBL15467036 | 0.94 | TRPM8 (0.60) | TRPM8PDE2AP2RX7TRPV1TLR7 | |
| SCHEMBL15567194 | 0.94 | TRPM8 (0.57) | TRPM8PDE2AP2RX7TRPV1ABL1 | |
| SCHEMBL15567196 | 0.94 | TRPM8 (0.57) | TRPM8PDE2AP2RX7TRPV1ABL1 | |
| SCHEMBL15567942 | 0.93 | TRPM8 (0.58) | TRPM8PDE2AP2RX7TRPV1TLR7 | |
| SCHEMBL16414357 | 0.93 | TRPM8 (0.58) | TRPM8PDE2AP2RX7TRPV1TLR7 | |
| SCHEMBL15567675 | 0.93 | TRPM8 (0.58) | TRPM8PDE2AP2RX7TRPV1TLR7 | |
| SCHEMBL15567674 | 0.93 | TRPM8 (0.58) | TRPM8PDE2AP2RX7TRPV1TLR7 | |
| SCHEMBL16414152 | 0.93 | TRPM8 (0.58) | TRPM8PDE2AP2RX7TRPV1TLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150031668-A1 | CHROMAN DERIVATIVES AS TRPM8 INHIBITORS | AMGEN INC (US) | 2015-01-29 | — | — | US | claimed |
| WO-2014025651-A1 | CHROMAN DERIVATIVES AS TRPM8 INHIBITORS | AMGEN INC. (US) | 2014-02-13 | — | — | WO | claimed |
| US-20150031668-A1 | CHROMAN DERIVATIVES AS TRPM8 INHIBITORS | AMGEN INC (US) | 2015-01-29 | — | — | US | disclosed |
| US-20150031668-A1 | CHROMAN DERIVATIVES AS TRPM8 INHIBITORS | AMGEN INC (US) | 2015-01-29 | — | — | US | disclosed |
| WO-2014025651-A1 | CHROMAN DERIVATIVES AS TRPM8 INHIBITORS | AMGEN INC. (US) | 2014-02-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150031668-A1 | CHROMAN DERIVATIVES AS TRPM8 INHIBITORS | TRPM8, TRPM5, TRPM7 | TRPM8 1/4885PDE2A 891/4885P2RX7 178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.